EE+ POEM Archive
Risk of melanoma increases minimally, if at all, with the use of PDE5 inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Risk of Melanoma Increases Minimally, if at All, With the Use of PDE5 Inhibitors." EE+ POEM Archive, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/428389/all/Risk_of_melanoma_increases_minimally__if_at_all__with_the_use_of_PDE5_inhibitors.
Risk of melanoma increases minimally, if at all, with the use of PDE5 inhibitors. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428389/all/Risk_of_melanoma_increases_minimally__if_at_all__with_the_use_of_PDE5_inhibitors. Accessed February 15, 2025.
Risk of melanoma increases minimally, if at all, with the use of PDE5 inhibitors. (2025). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428389/all/Risk_of_melanoma_increases_minimally__if_at_all__with_the_use_of_PDE5_inhibitors
Risk of Melanoma Increases Minimally, if at All, With the Use of PDE5 Inhibitors [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2025. [cited 2025 February 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428389/all/Risk_of_melanoma_increases_minimally__if_at_all__with_the_use_of_PDE5_inhibitors.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Risk of melanoma increases minimally, if at all, with the use of PDE5 inhibitors
ID - 428389
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428389/all/Risk_of_melanoma_increases_minimally__if_at_all__with_the_use_of_PDE5_inhibitors
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
